NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024. Second Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.2 million, up 7% Total revenues were $5.0 million, up 21% Gross Profit Margin was 84%, up from ...